Specific Interactions of Antitumor Metallocenes with Deoxydinucleoside Monophosphates

Fine-tuning the cytotoxicity of ruthenium(II) arene compounds to enhance selectivity against breast cancers

Ruthenium-based complexes have been suggested as promising anticancer drugs exhibiting reduced general toxicity compared to platinum-based drugs. In particular, Ru(η6-arene)(PTA)Cl2 (PTA = 1,3,5-triaza-7-phosphaadamantane), or RAPTA, complexes have demonstrated efficacy against breast cancer by suppressing metastasis, tumorigenicity, and inhibiting the replication of the human tumor suppressor gene BRCA1. However, RAPTA compounds have limited cytotoxicity, and therefore comparatively high doses are required. This study explores the activity of a series of RAPTA-like ruthenium(II) arene compounds against MCF-7 and MDA-MB-231 breast cancer cell lines and [Ru(η6-toluene)(PPh3)2Cl]+ was identified as a promising candidate. Notably, [Ru(η6-toluene)(PPh3)2Cl]Cl was found to be remarkably stable and highly cytotoxic, and selective to breast cancer cells. The minor groove of DNA was identified as a relevant target.

Titanocene binding to oligonucleotides

The binding of titanocene to DNA and RNA was examined by means of electrospray mass spectrometry. Titanocene served as a model for its therapeutically active derivatives. The binding preferences were probed by competition experiments with oligonucleotides of varying nucleobase compositions and sequences. Results from competition experiments revealed a generally increased preference for the binding to phosphate groups adjacent to thymidines, which is affected by the nucleobase sequence of T-rich oligonucleotides. More detailed information about the binding sites was obtained from tandem mass spectrometric experiments. The binding of the transition metal coordination center significantly altered the fragment ion patterns of the oligonucleotides. RNA was found to be less prone to adduct formation, due to intramolecular interactions. The findings from experiments on DNA and RNA were complemented by the examination of backbone- and ribose-modified oligonucleotides.